UroGen Pharma (URGN) Other financing activities (2017 - 2026)

UroGen Pharma (URGN) has 9 years of Other financing activities data on file, last reported at $179000.0 in Q1 2026.

• Quarterly Other financing activities rose 496.67% year-over-year to $179000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 88.64% YoY) and the FY2025 annual result came in at $2.0 million, down 89.42% from the prior year.
• Other financing activities slipped to $179000.0 in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $47.9 million in Q3 2023 to a low of $16000.0 in Q2 2022.
• A 5-year average of $5.9 million and a median of $340000.0 in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities soared 37133.33% — and 2025, when it slumped 98.41%.
• Tracing URGN's Other financing activities over 5 years: stood at $378000.0 in 2022, then jumped by 12568.25% to $47.9 million in 2023, then sank by 61.07% to $18.6 million in 2024, then slumped by 92.8% to $1.3 million in 2025, then sank by 86.67% to $179000.0 in 2026.
• The last three Other financing activities figures came in at $179000.0 (Q1 2026), $1.3 million (Q4 2025), and $302000.0 (Q3 2025), per Business Quant data.